冠心病合并2型糖尿病应用曲美他嗪治疗的效果分析  

Analysis of the Effect of Trimetazidine Treatment on Coronary Heart Disease Complicated with Type 2 Diabetes

作　　者：练育芳[1] LIAN Yu-fang(Department of Cardiology,Dongtai People's Hospital,Dongtai,Jiangsu Province,224200 China)

机构地区：[1]江苏省东台市人民医院心血管内科,江苏东台224200

出　　处：《糖尿病新世界》2021年第4期117-119,共3页Diabetes New World Magazine

摘　　要：目的探析冠心病合并2型糖尿病应用曲美他嗪治疗的临床疗效。方法该文对该院2017年1月—2019年12月收治的75例冠心病合并2型糖尿病患者进行分组研究,采取常规治疗患者为对照组(n=37),基于对照组给予曲美他嗪治疗患者为观察组(n=38),对比患者血脂、血糖及心功能差异。结果观察组患者HDL(3.11±1.27)、TG(1.56±0.28)、LDL(3.05±0.36)、TC(4.48±0.22)mmol/L优于对照组,差异有统计学意义(t=5.285、10.928、5.746、14.440,P<0.05)。观察组患者FBG(6.68±0.59)mmol/L、HbA1c(6.98±0.39)%优于对照组,差异有统计学意义(t=4.627、5.039,P<0.05)。观察组治疗后左心室射血分数(52.34±2.86)%、左心室短轴缩短率(25.46±1.92)%、心肌血流量(77.93±2.38)mL/min均优于对照组,差异有统计学意义(t=11.014、5.234、23.311,P<0.05)。结论冠心病合并2型糖尿病患者应用曲美他嗪治疗,患者血脂、血糖水平与心功能改善效果理想。Objective To explore the clinical efficacy of trimetazidine in the treatment of coronary heart disease complicated with type 2 diabetes.Methods This article conducted a group study of 75 patients with coronary heart disease and type 2 diabetes who were admitted to the hospital from January 2017 to December 2019.Patients with conventional treatment were taken as the control group(n=37),and trimetazidine was administered based on the control group as the observation group(n=38),and the differences in blood lipids,blood glucose and heart function of the patients were compared.Results HDL(3.11±1.27)mmol/L,TG(1.56±0.28)mmol/L,LDL(3.05±0.36)mmol/L,and TC(4.48±0.22)mmol/L of the observation group were better than those of the control group,the difference was statistically significant(t=5.285,10.928,5.746,14.440,P<0.05).In the observation group,FBG(6.68±0.59)mmol/L and HbA1c(6.98±0.39)%were better than those in the control group,the difference was statistically significant(t=4.627,5.039,P<0.05).After treatment,the observation group left ventricular ejection fraction(52.34±2.86)%,left ventricular short axis shortening rate(25.46±1.92)%,and myocardial blood flow(77.93±2.38)mL/min,which were better than those of the control group,the difference was statistically significant(t=11.014,5.234,23.311,P<0.05).Conclusion Patients with coronary heart disease and type 2 diabetes mellitus are treated with trimetazidine,and the effect of improving blood lipids,blood glucose levels and cardiac function is satisfactory.

关 键 词：2型糖尿病 冠心病 曲美他嗪 效果 

分 类 号：R4[医药卫生—临床医学]